Tuesday, 20 Aug 2019

You are here

Ten Contemporary Challenges Facing Lupus Treatment

A group of French researchers have pooled their interests to identify the challenges ahead in the management of patients with systemic lupus erythematosus (SLE). 

This introspective review puts forth the authors’ perceptions of the 10 most important contemporary challenges in the management of SLE. The paper represents the roundtable consensus of a multidisciplinary team of clinicians, pharmacists and researchers from a national centre for rare autoimmune and systemic diseases (Strasbourg, France).

The 10 main contemporary challenges in SLE include: 

  • T2T: favouring disease remission (or low disease activity).
  • Limiting the use of glucocorticoids.
  • Deriving more comprehensive tools for the evaluation of disease activity.
  • Developing more effective (and better tolerated) drugs (and more successful trials).
  • Dissecting the heterogeneity of the disease at the molecular and genetic levels.
  • Identifying relevant biomarkers for individualised treatment.
  • Managing fertility and pregnancy.
  • Managing comorbidities(e.g., cardiovascular risk, infections, osteoporosis).
  • Improving the network of care (the patients’ perspective).
  • Favouring a holistic approach (integrating fatigue, adherence to treatment, physical activity).

These 10 contemporary challenges in SLE may be considered as a roadmap for those involved in the daily care of patients with SLE, as well as for researchers who may wish to contribute to an improved management of this rare and complex disease.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Sjogren's Syndrome at Risk for Psychiatric Disorders

A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS). 

Abatacept Disappoints in Systemic Sclerosis

A 12‐month, Phase 2 trial has shown that subcutaneous abatacept was well tolerated in patients with diffuse cutaneous systemic sclerosis (dcSSc), but failed to significantly change the skin outcomes as measured by the change in modified Rodnan skin score (mRSS)

FDA AAC Splits Vote in Favor of Nintedanib for Scleroderma Interstitial Lung Disease

The FDA convened Arthritis Advisory Committee to consider nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and voted 10-7 in favor of approving the drug for this new indication.